Large and growing segments of the United States population consume seafood or engage in marine recreation. These activities provide significant benefits but also bring risk of exposure to marineborne illness. To manage these risks, it is important to understand the incidence and cost of marineborne disease. We review the literature and surveillance/monitoring data to determine the annual incidence of disease and health consequences due to marine-borne pathogens from seafood consumption and beach recreation in the USA. Using this data, we employ a cost-of-illness model to estimate economic impacts. Our results suggest that health consequences due to marine-borne pathogens in the USA have annual costs on the order of US$900 million. This includes US$350 million due to pathogens and marine toxins specifically identified as causing food-borne disease, an estimated US$300 million due to seafood-borne disease with unknown etiology, US$30 million from direct exposure to the Vibrio species, and US$300 million due to gastrointestinal illness from beach recreation. Although there is considerable uncertainty about the degree of underreporting of certain pathogen-specific acute marine-related illnesses, the conservative assumptions we have used in constructing our estimate suggest that it should be considered a lower bound on true costs.
INTRODUCTION
The marine environment contains millions of microbial pathogens and toxins that are both naturally occurring and foreign; and many of these microbial agents have been linked to human diseases (Thompson et al. ) . As coastal urban communities grow and our reliance on marine environments for aquaculture and recreation increases, so do the risks of disease from these pathogens. The primary goal of this study is to produce an estimate of the annual human health costs for residents of the USA due to exposure to selected pathogens and toxins from the marine environment. This estimate will allow researchers and public health officials to target pathogens with the greatest economic impact to public health, and may lead to improvements in monitoring of marine waters by producing an economically optimal management strategy. We also identify areas for further research to develop a more complete economic analysis.
The pathogen-specific cost estimate in this paper includes two viral pathogens, 15 bacterial pathogens, and four marine toxins. Many of these pathogens and toxins are endemic to the marine environment (e.g. the Vibrio species); others enter the water via fecal contamination (e.g. Norwalk virus, Salmonella and Campylobacter). Over the past 15 years, about 9% of seafood-related outbreaks with known etiology were caused by viruses (predominately Norwalk virus), 25% were caused by bacteria and 64% were from marine toxins (CSPI ).
The pathogens selected for this analysis are those for which there is evidence of links to human disease, with documented cases in the USA. Seafood is thought to be the most common route of exposure, although this may depend in part on the limited data on illnesses due to direct exposure and the lack of reliable methods for detecting specific pathogens in marine waters. Our approach excludes marine agents for which there is too little surveillance to obtain accurate measurements, such as parasites, anthropogenic chemical agents, persistent organic pollutants, heavy metals and pharmaceutically active products.
Potential chronic health effects due to these agents may contribute significantly to health costs (AMAP ; Judd et al.
; McDonald & Reimer ).
The two primary routes of transmission for marineborne disease are seafood consumption and direct exposure from beach recreational environments. Direct exposure includes accidental ingestion of contaminated water, exposure to skin, eyes and ears during swimming and the inhalation of aerosolized toxins while at the beach. The methods used to estimate disease incidence and cost are different for each route of transmission, largely because of differences in case reporting and pathogen identification. Even when help is sought by the patient, health care professionals may either misdiagnose or fail to recognize the illness as marine borne, may not report the illness to public health officials, or may not obtain specimens for diagnosis. When specimens are available, laboratories are not always able to perform the necessary diagnostic tests.
The lack of diagnostic techniques often makes it impossible to identify the pathogenic etiology (Olsen et al. ) . In 1998 improvements in the laboratory method for detection of Norwalk virus resulted in increases in seafood-borne disease attributed to Norwalk (CSPI ).
Prior to the change in methodology, few cases of seafood-borne illness were attributed to Norwalk virus. A recent study has shown that Staphylococcus aureus, including MRSA (methicillin-resistant S. aureus) and MSSA (methicillin-sensitive S. aureus), has been found in recreational marine environments from bather shedding (Plano et al. ) . Given the high number of S. aureus infections in hospitals (McCaig et al. ; Moran et al. ) and number of deaths due to this bacteria (Klein et al. ) , inclusion of these illnesses could significantly increase the cost estimate of marine-borne illness.
While the incidence of seafood-borne disease is largely estimated from surveillance data, illnesses from direct exposure are estimated primarily using modeling techniques. An exception is the Cholera and Other Vibrio Illness Surveillance (COVIS) system established in 1988 to record the number of illnesses from exposure to the bacterial Vibrio species. Although most Vibrio infections result from ingestion of contaminated seafood, 12-28% are from direct exposure to marine water (CDC -) resulting in wound infections (Shapiro et al. ) .
Most incidence estimates for disease from direct exposure model the number of excess cases of gastrointestinal illness using risk relationships between polluted water and illness. These relationships are derived from randomized trial studies (Fleisher et al. ) and prospective cohort studies (Cabelli et al. ) , and show that swimmers Using these relationships and an exposure index based on Enterococcus levels and swimming exposure, Given et al.
() estimated an excess 627,800-1,479,200 cases of gastrointestinal illnesses at 28 beaches in Southern California, with an economic loss of US$21-51 million. Similarly, 36,778 excess cases of gastrointestinal illnesses per year were found at two beaches in Southern California, resulting in a $3.3 million loss (Turbow et al. ) . Although these studies were limited to a small region where recreational beach attendance is high, it is likely that public health costs exist at other recreational beaches around the country.
The adverse effect of ocean exposure on health outcomes is not limited to fecally contaminated waters. Aerosolized brevetoxins produced by the marine algae Karenia brevis have been associated with respiratory symptoms among asthmatics on beaches in Southern Florida. Studies have found a significant increase in intensity of respiratory symptoms and emergency room admissions for respiratory illnesses when an algae bloom was present (Kirkpatrick et al. ) .
The pathogenic etiology of most illnesses from direct exposure to ocean water or the marine environment is not well understood. Fecal coliform levels are typically used as indicators of fecal contamination, but research linking specific pathogens to disease outbreaks is complicated by the broad spectrum of pathogens in beach water (NRC ) and the high degree of temporal and spatial variability (Boehm ).
For these reasons most studies to date have been limited to estimating costs associated with general beach exposure.
METHODS
The first step to determine a cost estimate is to identify the marine-borne pathogens and toxins that are major disease agents rather than those causing a few sporadic cases.
Although many pathogens in the marine environment are capable of causing human illness, we focus on those that were likely to have a significant economic impact. Sporadic cases are unlikely to account for significant costs unless the disease is life threatening or requires extensive medical Other than for Vibrio species and K. brevis, we find that there are insufficient data to estimate with enough accuracy the pathogen-specific costs of illness due to direct exposure.
We therefore adopt a general health cost estimate for direct exposure by extrapolating findings from a beach exposure study in Southern California to the rest of the country.
Disease incidence

Seafood borne
We use information from the CDC's surveillance systems to estimate the number of cases of seafood-borne illness (Table 1) , taking into account limitations of surveillance data and underreporting. For each pathogen, we first determine an average annual number of surveillance cases caused by seafood consumption, either from outbreak data (which exclude sporadic cases or cases not identified as part of an outbreak) or from passive surveillance data (which include sporadic cases). For most pathogens, a scaling ratio is applied to estimate the total reported cases that take into account the exclusion of sporadic cases and/or cases not captured by passive or outbreak surveillance.
The method for determining the scaling ratio varies by pathogen and depends on the type of surveillance through which that pathogen is reportable.
Pathogens only reportable through outbreak surveillance Once we adjust the number of outbreak or passive surveillance cases to reflect the total reported seafood-borne cases, we apply an underreporting ratio to calculate a more probable incidence of disease. This ratio accounts for unreported cases due to a failure of medical practitioners to report the illness to public health authorities, limitations in laboratory practices (i.e. failing to perform the necessary diagnostic test, the physician does not obtain a specimen) and/or the ill person's decision not to seek medical help.
For seafood-borne illness we assign one of three underreporting ratios to the first two categories (lost productivity and physician visit) depending on illness severity: 38 times the reported number for mild cases, 20 times the reported number for moderately severe cases, and 2 times the reported number for very severe cases (Mead et al. ) .
For pathogens with no known underreporting ratio, we apply one of these estimates depending on the type and duration of the disease symptoms. We apply a weighted average underreporting ratio of 67.5 for CFP in this study (based on underreporting in Hawaii and Florida [Hoagland et al. ] ) and an underreporting ratio of 10 is used for PSP and NSP based on an estimate from Todd ().
Hospitalizations and deaths are also underreported for several reasons (Mead et al. ) , although to a lesser degree. We apply one underreporting ratio to all pathogens and marine toxins in the two higher severities. Because there is little published information on the number of seafood-borne illnesses that lead to hospitalization or premature death, our estimate is based on a study of notifiable infectious diseases that found only 79% of AIDS, tuberculosis and sexually transmitted disease cases were reported (Doyle et al. ) . Given the severity of these illnesses compared with marine-borne diseases, it is likely that the fraction of reported cases in our study is substantially lower. However, in the absence of specific data for the more severe foodborne diseases, we apply an underreporting estimate of 25% to each of these categories across all pathogens.
Direct exposure
The number of illnesses from infection of Vibrio vulnificus, (CDC a, b). We estimate the total number of respiratory illnesses from aerosolized K. brevis exposure by assuming that the annual predicted 218 emergency room 
Estimating cost
Once an incidence estimate is determined, we assign a cost to each of the four severity categories. We use the proportion of illnesses that fall into each category to determine a total cost for each pathogen and marine toxin, and exposure to contaminated beach water.
Proportions
To estimate the proportion of cases that falls into each category, we used several data sources and follow the method for categorization that was used by ERS ( Buzby et al. (1996) . g 1-sum of proportions for categories 1-4. h Given the severity of the illness and the high proportion of hospitalized cases we make the assumption that all cases seek some level of medical care. i CDC, COVIS (1999 COVIS ( -2006 
Sensitivity analysis
Our model includes several parameters that are difficult to measure accurately. In several instances, we had to make assumptions to estimate these parameters in our model and, as a result, our cost estimates are characterized by varying degrees of uncertainty. To quantify this uncertainty we conduct a sensitivity analysis for seafood-borne illness costs and pathogen-specific illness from direct exposure. While there is also uncertainty in the model estimates for illness from beach contamination and from unknown etiology, there were too few parameters to conduct a detailed sensitivity analysis. The estimates of illness from beach contamination and from unknown etiology should be considered order of magnitude estimates.
For seafood-borne and pathogen-specific illness estimates, we perturb the scaling ratio, the underreporting ratio and the proportion by 20% (two pathogens have scaling ratios of one, so they are not varied since a scaling ratio cannot be less than one). Because it is necessary to maintain the unit sum across the severity category proportions, we modified the proportions in the adjacent categories when perturbing these proportions based on the rationale that uncertainty in a proportion would likely be reflected in the adjacent category. For example, while is it possible that 20% of the people who did not seek medical care (category 1) did in fact see a doctor (category 2), it is less likely that a person who was incorrectly determined to have not sought medical care (category 1) in fact died (category 4).
RESULTS AND DISCUSSION
We calculate the annual health costs of seafood-borne diseases to be US$350 million and the costs of illnesses from direct exposure to V. vulnificus, V. parahaemolyticus, V. alginolyticus and aerosolized K. brevis to be over US$30 million. We estimate the cost of the 5 million cases of gastrointestinal illness from beach exposure to be almost US$300 million. Combined, this suggests that marine-borne diseases with known etiology in the USA have annual health costs on the order of US$600 million (Figure 1 ).
Our estimate of pathogen-specific, seafood-borne illness cost excludes cases with unknown pathogenic etiology, including those that were misdiagnosed or could not be identified as marine borne and therefore is likely an underestimate of the total cost of seafood-borne disease. Over 80% of the estimated 76 million annual cases of foodborne disease in the USA have an unknown etiology (Mead et al. ) . Assuming that 5% of the 62 million cases with unknown etiology are from seafood (Huss et al.
; CSPI ), the number of additional seafood-borne cases could be over 3 million with costs of almost $300 million (we assume here that these cases have severity proportions similar to those of Norwalk virus). Including the cost of seafood-borne illnesses with unknown etiology almost doubles the total cost of seafood-borne illness.
Cost of seafood-borne illness
Our results indicate that premature deaths contribute most to the total costs of seafood-borne illness (US$306 million) (Table 2) , with the remainder due to medical care (US$25 million for physician visits and US$6 million for hospitalizations) and lost productivity (US$15 million). Vibrio vulnificus is the most costly marine-borne pathogen, accounting for about a third of the total seafood-borne costs and over 85% of the costs of Vibrio infections from direct exposure (Figure 1) . This is primarily a result of the high rate of premature death among V. vulnificus cases.
With a death rate of 31% for seafood-borne infection and 18% for infections from direct exposure, the cost from premature death (US$238 million) accounts for 99% of the total V. vulnificus health costs and 75% of the total cost of premature death. 
Cost of illness from direct or recreational exposure
The health costs from direct exposure are more difficult to assess, but results from the limited surveillance data and the extrapolation analyses suggest that they are on the order of US$300 million/year (Table 2) . Using incidence data from COVIS, it is estimated that V. vulnificus infections cost over US$28 million while V. alginolyticus cost over US$1 million. Vibrio parahaemolyticus infections are less common from direct exposure and have costs of about US$1.5 million compared with the US$21 million from ingestion of seafood. Respiratory illness from K. brevis corresponds to a cost of over US$2 million. The health costs from contaminated beach water are the largest component of direct exposure health costs. We estimate a total of over 5 million cases of excess gastrointestinal illness due to beach exposure, corresponding to almost US$300 million/year.
Sensitivity analysis
To evaluate cost model sensitivity, we perturbed the model variables by 20% in various combinations to yield 243 different cost estimates for all of the seafood-borne pathogens except Norwalk virus, which had only 81 cost combinations because no scaling ratio was used. Pathogens causing illness from direct contact had only nine cost combinations because no scaling ratio or underreporting ratio was used. In the sensitivity analysis, the total cost for pathogen-specific illness ranged from US$166 million to US$967 million.
However, random sampling of the sensitivity results indicates that when the lower and upper 5% of the possible combinations are excluded, the total cost range is approximately US$300 million to US$550 million, considerably closer to the point estimate. We examined the impact of death on the cost uncertainty because it accounts for a large fraction of the total cost. To assess whether the high cost of death or a high death rate among a few pathogens was driving the total cost uncertainty, we also ran the sensitivity analysis both with an altered cost of a premature death and by removing the cost of death from the estimate. Although the cost range without death decreased under the different scenarios, the upper and lower bounds of the cost estimates remained proportionally similar to the point cost estimate, suggesting that death alone does not primarily drive the range of uncertainty.
One goal of this study was to identify the pathogens and marine toxins that prevention and monitoring efforts should target to produce the most significant economic benefits.
Vibrio vulnificus is the most costly pathogen in our study with an annual cost of illness ten times higher than any other pathogen; it makes up 66% of the seafood-borne illness health costs and 26% of the total health costs. The high costs are primarily driven by high death rates, underscoring the public health importance of this illness. Without the cost of death included, the total health cost from illness with known etiology is US$335 millionabout 50% of the overall cost. The cost of premature death accounts for almost 90% of the total seafood-borne health costs. The cost model assumes that the VSL is US$5 million.
Although VSL in the literature can range from US$0.5 million to US$21 million (Viscusi & Aldy ), the commonly used range is substantially narrower, from about US$5.5 million to US$7.5 million (Kniesner et al. ) . Among federal agencies, the FDA estimates a VSL to be about US$8 million, the EPA has a slightly lower estimate of US$7 million, and the ERS/USDA estimate is about US$5.5 million. We have used the lower end of this range, and increases in the VSL would substantially increase the total health cost estimates.
In addition to the conservative parameter estimates, the cost estimate for marine-borne illness may represent a lower bound of the true costs because we do not include costs that are difficult to measure such as chronic effects and pain and suffering. A recent study that used a cost-of-illness model developed by the FDA that included a measure of chronic pain and suffering and functional disability found the total cost of food-borne illness to be US$152 billion (Scharff et al. ; Scharff ). The productivity losses associated with pain and suffering are also likely to be important, but assignment of reliable cost estimates introduces additional uncertainly. We used a lost productivity estimate that only included lost days of work and forgone compensation, so our cost per case is about US$1,300 versus a cost of about US$1,800 per case in the alternative cost model (Scharff ) .
Similarly, chronic health effects from marine-borne illnesses may introduce substantially higher costs than we have assumed. While there are few data from which to quantify the prevalence of long-term symptoms, it has been estimated that chronic sequelae may occur in 2-3% of food-borne illnesses generally, and that the costs of these health consequences could be greater than the costs of the acute symptoms (Lindsay ). In the absence of a model designed specifically to estimate the cost of seafood-borne illness, we use a model that was developed to estimate the cost of food-borne illness in general.
There may be differences, however, between the average American and the average seafood consumer. The average American consumes less seafood than other meat and poultry. 
CONCLUSIONS
We estimate the acute health cost of marine-borne disease in the USA to be close to a billion dollars annually, with seafood-borne disease making up two-thirds of the cost, and illness from direct exposure to the marine environment accounting for the rest. We identify several pathogens that contribute substantially to these costs, notably the Vibrio species, CFP and Norwalk virus. Incomplete reporting of marine-borne illnesses, unknown pathogenic etiology of many food-borne cases, and limitations in identifying specific pathogens in beach recreation cases introduce considerable uncertainty into the overall estimate. Future research should focus on resolving these uncertainties, on extending the estimate to include the cost of chronic health effects and pain and suffering, and determining an economically optimal policy response to preventing marine-borne illness.
Relative to the heath costs of other illnesses, such as cancer, HIV/AIDS and diabetes, the cost of marine-borne illness is small. Annual direct medical costs are estimated to be US$74 billion for cancer (Meropol & One goal of estimating the cost of marine-borne illness is to determine the economically optimal policy response to managing marine health. If the cost of preventing marineborne illness is significantly outside the range of cost uncertainty, then from a policy point of view, a more precise estimate may not be necessary. Future research should focus on determining the appropriate policy for preventing marine-borne illness based on the optimal economic response and compare it with other public health problems.
